DNAAF2 (Gene)

Organism:

Homo sapiens

Synonyms:C14orf104, CILD10, DNAAF2, ENTREZ:55172, HGNC:20188, KTU, MIM:612517, NM_001083908, NM_001378453, NM_018139, NP_001077377, NP_001365382, NP_060609, PF13, dynein axonemal assembly factor 2

Omim:OMIM:612517

Id:ENSG00000165506

Hgnc:HGNC:20188

Entrez:55172

Ensembl:ENSG00000165506

Description:dynein axonemal assembly factor 2

This gene encodes a highly conserved protein involved in the preassembly of dynein arm complexes which power cilia. These complexes are found in some cilia and are assembled in the cytoplasm prior to transport for cilia formation. Mutations in this gene have been associated with primary ciliary dyskinesia. Multiple transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Oct 2009]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View DNAAF2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with DNAAF2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using DNAAF2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for DNAAF2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with DNAAF2.

Results found

Linked to

	Label	Description
	GSE195663 cisplatin 7 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE102757 1 V 0 PANOBINOSTAT MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 11 V 6 SULFORAPHANE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 5 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 11 V 9 CRIZOTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 elesclomol SU-DHL-4 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169152 3 V 6 IBRUTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE115395 2 V 4 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 7 V 1 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE102757 1 V 0 PANOBINOSTAT MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE48812 11 V 6 SULFORAPHANE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 6 V 5 CRIZOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 11 V 9 CRIZOTINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE228263 elesclomol SU-DHL-4 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE169152 3 V 6 IBRUTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE115395 2 V 4 ENZALUTAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE195663 7 V 1 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.